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infants may be particularly susceptible to the adverse
affects of CPB. It is well documented that CPB is an
inflammatory stimulus and that its use provokes a
whole body inflammatory reaction with endothelial cell
injury, adhesion molecule up-regulation,1 neutrophil
activation,2 and initiation of the coagulation cascade.3
Patients may also incur an ischemic injury to the lungs
during the course of CPB. These processes may result
in pulmonary dysfunction and excessive total body
edema, which in turn may result in increased ventilatory
and oxygen requirements and an inability to close the
chest.
Many investigators have documented in clinical stud-
ies and experimental preparations that the levels of a
C ardiopulmonary bypass (CPB) continues to be asso-ciated with significant morbidity despite the many
advances made in perfusion techniques. Neonates and
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METHYLPREDNISOLONE REDUCES THE INFLAMMATORY RESPONSE TO CARDIOPULMONARY
BYPASS IN NEONATAL PIGLETS: TIMING OF DOSE IS IMPORTANT
number of inflammatory mediators are elevated during
and after CPB.4-6 Although the significance of the ele-
vated levels is uncertain, it is clear that a substantial
inflammatory response is occurring. Efforts have also
been made to develop methods for reducing the inflam-
matory reaction caused by CPB in hopes that this will
reduce bypass-induced morbidity. These have included
the use of antibodies to specific cytokines or adhesion
molecules,7,8 soluble complement receptor,9 and bio-
compatible coatings for the extracorporeal circuit.10
Some of these strategies, including the use of glucocor-
ticoids, have been shown to reduce the levels of circu-
lating inflammatory mediators such as interleukins 6
and 8, C3a, and tumor necrosis factor–a (TNF-a ) after
CPB, but few have correlated reduced levels of cyto-
kines with improved outcome. In addition, most of the
strategies tested would be limited in their clinical appli-
cation because of the lack of general availability or the
prohibitive expense of the proposed agent or method,
and not to mention mechanisms too specific to inhibit
the redundant inflammatory cascade.
Clinical and laboratory experience has suggested that
the use of methylprednisolone sodium succinate given
before CPB may improve the course of CPB, leading to
less postoperative morbidity. This may have an impact
on ventilator time, intensive care unit and hospital
stays, and hospital costs. Methylprednisolone has the
advantage of being readily available and inexpensive.
Compared with many of the other selective anti-inflam-
matory agents that have been studied, it also offers the
advantage of inhibiting the inflammatory response at
many levels. Anecdotal evidence and several studies
suggest that, when used, methylprednisolone is fre-
quently administered either just before CPB or into the
extracorporeal circuit prime only. However, on the
basis of the mechanism of action of methylprednis-
olone, a matter of several hours should be required
before its peak effect is realized.
We hypothesized that administering methylpred-
nisolone before a cardiac operation would reduce the
inflammatory response to CPB in infants and that this
effect would cause a measurable improvement in pul-
monary function after bypass. Furthermore, we be-
lieved that administering methylprednisolone before
the operation would be more beneficial than giving it in
the circuit prime only. This laboratory study used an
infant pig model to test these hypotheses.
Material and methods
Animal preparation. One-week-old piglets were used for
all experiments with the approval of the institution’s Animal
Care and Use Committee. All animals were treated according
to “Guide for the Care and Use of Laboratory Animals”
(National Institutes of Health publication No. 85-23, revised
1985). Animals were premedicated with intramuscular keta-
mine hydrochloride (20 mg/kg) and acepromazine maleate (1
mg/kg). After endotracheal intubation and establishment of
an intravenous line, intravenous boluses of fentanyl citrate
(100 m g/kg) and pancuronium bromide (0.3 mg/kg) were
administered, and mechanical ventilation was begun with an
infant pressure cycled ventilator (Sechrist Industries,
Anaheim, Calif). Ventilator settings were adjusted to main-
tain a PO2 of 200 to 250 mm Hg and a PCO2 of 35 to 45 mm
Hg. Blood gases and hematocrit were measured with a GEM-
Stat Blood Gas/Electrolyte Monitor (Mallinckrodt Sensor
Systems Inc, Ann Arbor, Mich). Anesthesia was maintained
with a fentanyl citrate infusion (100 m g/kg per hour).
An 18-gauge catheter was inserted into the right femoral
artery for pressure and blood gas monitoring. A median ster-
notomy was performed, and a perivascular ultrasonic pul-
monary artery flow probe (Transonics, Inc, Ithaca, NY) was
fitted for cardiac output measurement. Micromanometers
(Millar Instruments, Houston, Tex) were inserted into the left
atrium, pulmonary artery, and right ventricle.
Experimental design. Piglets were initially divided into 2
groups. The control group received no additional premedica-
tion before CPB. The experimental group (Preop-MP)
received 30 mg/kg of methylprednisolone intravenously both
8 hours before the operation and immediately after the induc-
tion of anesthesia (approximately 1.5 hours before CPB). A
second experimental group (Prime-MP) received no methyl-
prednisolone before the operation, but 30 mg/kg of methyl-
prednisolone was added to the extracorporeal circuit prime.
Animals from each group underwent identical instrumenta-
tion and were each subjected to CPB and 45 minutes of deep
hypothermic circulatory arrest. After deep hypothermic cir-
culatory arrest, the animals were rewarmed and weaned from
CPB.
Data collection. After instrumentation was complete and
the animals were observed for hemodynamic stability, base-
line data were collected that included an arterial blood gas,
arterial blood pressure, heart rate, and ventilator settings.
Data from the flow probe and micromanometers were digi-
tized at 500 Hz for 8 seconds and stored as a computer file for
later analysis. Static pulmonary compliance was measured
with a pediatric pulmonary function laboratory (Sensor-
medics, Inc, Yorba Linda, Calif). The same data were again
collected at 30 and 60 minutes after discontinuation of CPB.
Each computer file containing pressure and flow data was
analyzed with custom software and a personal computer. Left
atrial pressure (LAP), mean pulmonary artery pressure
(MPAP), cardiac output, and pulmonary vascular resistance
(PVR) were derived for each experimental stage. The cardiac
output was indexed by dividing by the animals’ preoperative
body weight.
Each animal was weighed to the nearest 10 g both before
and after the experiment to determine total body weight gain.
Peripheral lung biopsy specimens weighing 1 to 2 g were
taken from the anterior right middle lobe of each animal at
the conclusion of each experiment. The lung biopsy speci-
mens were weighed wet, then desiccated in a warming oven,
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and reweighed dry to determine lung water content. A careful
record was kept of the extracorporeal circuit fluid balance for
each animal.
CPB. The extracorporeal circuit included a Minimax Plus
Hollow Fiber Oxygenator/Heat Exchanger (Medtronic, Inc,
Anaheim, Calif) and a standard roller pump (Stöckert-Shiley,
Irvine, Calif). It was primed with fresh donor pig whole blood
and lactated Ringer’s solution mixed to obtain a hematocrit of
23% to 25%, 2000 U heparin sodium, 400 m g fentanyl citrate,
2 mg pancuronium bromide, and sodium bicarbonate to
achieve a pH of approximately 7.40. The donor blood was fil-
tered with a high efficiency leukocyte removal filter (model
RCXLTM2; Pall Biomedical, Inc, Fajardo, Puerto Rico).
After instrumentation, baseline data acquisition, and sys-
temic heparinization (300 units/kg), the aortic root and right
atrial appendage were cannulated through purse-string
sutures. Normothermic CPB was established at a flow rate of
100 mL · kg–1 · min–1. The animal was perfusion cooled to
18°C over 20 minutes then exsanguinated to the cardiotomy
reservoir. After 45 minutes of circulatory arrest, the animal
was reperfused and rewarmed over approximately 40 minutes
to normothermia. After reaching 36°C, CPB was discontin-
ued. During cooling and rewarming, alpha-stat strategy was
used to manage arterial blood gases. 
Statistical analysis. Variables measured at only 1 point in
the study (eg, lung water content) were made by single factor
analysis of variance. Post-hoc comparisons between the
groups were made by unpaired t test with the Bonferroni
modification. All variables measured over the course of the
experiment were compared between groups by 2-way repeat-
ed measures of analysis of variance. Post-hoc comparisons,
where appropriate, were made by the Scheffé test. Results for
each group are expressed as the mean ± SD.
Results
Pulmonary hemodynamics. There were no differ-
ences between the groups at baseline in cardiac index
(P = .32), LAP (P = .70), MPAP (P = .39), or PVR (P
= .13), although PVR tended to be lower and cardiac
index tended to be higher in the Preop-MP group than
in the other 2 groups (Table I). There were no signifi-
cant differences in LAP between any of the groups over
the course of the study (P = .63).
MPAP was significantly higher than baseline at 30
minutes and 60 minutes after CPB in both the control
group (P < .0001 for both) and the Prime-MP group (P
= .01 and .03, respectively) but not in the Preop-MP
group. The increase in MPAP over the course of the
study was significantly greater in the control group
than in either experimental group (P = .00001 vs
Preop-MP and P = .0004 vs Prime-MP) but was also
significantly greater in the Prime-MP group than in the
Preop-MP group (P = .05).
PVR was significantly higher at 30 and 60 minutes
after CPB compared with baseline in the control group
(P = .0002 for both) and the Prime-MP group (P = .05
and P = .0002, respectively) but was not significantly
higher than baseline in the Preop-MP group. The
increase in PVR after CPB was greater in both the con-
trol group (P = .007) and the Prime-MP group (P = .04)
compared with the Preop-MP group. There was no dif-
ference in the increase in PVR between the control and
Prime-MP groups. These data are shown in Fig 1.
The cardiac index was significantly lower than base-
line at 60 minutes after CPB in the control (P = .02)
and prime (P = .002) groups, but not in the Preop-MP
group.
Pulmonary function. There were no significant dif-
ferences between the groups in static pulmonary com-
pliance (C
stat) or alveolar-arterial oxygen gradient (A-a
gradient) at baseline. C
stat was significantly worse
(lower) at 30 and 60 minutes after bypass in the control
(P < .00001 for both) and Prime-MP (P = .004 and .002,
respectively) groups but not in the Preop-MP group.
The decrement in C
stat over the course of the study was
significantly different between the control and Preop-
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Table I. Hemodynamic data
Variable Stage Control Prime-MP Preop-MP
LAP (mm Hg) Baseline 5.2 ± 2.1 4.1 ± 2.1 4.7 ± 2.6
Post 30 4.2 ± 1.6 3.8 ± 1.7 4.4 ± 1.5
Post 60 4.3 ± 1.7 3.1 ± 1.6 3.9 ± 1.3
MPAP (mm Hg) Baseline 8.0 ± 4.3 9.6 ± 1.9 6.7 ± 3.0
Post 30 30.3 ± 3.6 19.5 ± 7.0 12.2 ± 2.4
Post 60 29.7 ± 4.3 19.6 ± 5.9 17.2 ± 5.4
Cardiac index (mL · min–1 · kg–1) Baseline 112 ± 21 105 ± 23 126 ± 28
Post 30 87 ± 9 93 ± 12 110 ± 38
Post 60 76 ± 18 69 ± 24 96 ± 31
Heart rate (beats/min) Baseline 163 ± 30 169 ± 22 124 ± 15
Post 30 176 ± 25 170 ± 21 147 ± 15
Post 60 189 ± 28 166 ± 29 151 ± 17
Values expressed as mean ± standard deviation.
MP groups (P = .016). The Prime-MP group, which fell
between the control and Preop-MP groups, did not dif-
fer significantly from either group with respect to the
change in C
stat over time. These data are shown in Fig 2.
The A-a gradient was significantly higher than base-
line at 30 and 60 minutes after CPB in the control
group (P = .0001 for both). In the Prime-MP group, the
A-a gradient only tended toward higher than baseline at
30 minutes after CPB (P = .07) but was significantly
greater at 60 minutes after CPB (P = .02). In the Preop-
MP group, the A-a gradient after CPB was not signifi-
cantly higher than baseline. With respect to the increase
in the A-a gradient over the course of the study, there
was a statistically significant difference between the
control and Preop-MP groups (P = .0003) and the con-
trol and Prime-MP groups (P = .01). The A-a gradient
in the Prime-MP group increased relative to the Preop-
MP group, but this difference was not statistically sig-
nificant (P = .07). These data are shown in Fig 3.
Weight gain/lung water. There was no significant
difference in preoperative body weight between the
groups. The body weights in each group were signifi-
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Fig 1. The PVR is shown for each group at each experimen-
tal stage. PVR is significantly higher than baseline in the con-
trol and Prime-MP groups. PVR in the Preop-MP group is
significantly lower compared with the control group at 30
minutes (Post 30) and at 60 minutes after CPB (Post 60). *P
< .05; †P = .013; ‡P = .036.
Fig 2. The static pulmonary compliance is shown for each
group at each experimental stage. Measurements were made
at before CPB (baseline) and at 30 minutes (Post 30) and 60
minutes (Post 60) after CPB. The C
stat is significantly lower
than baseline at Post 30 and Post 60 in the control and the
Prime-MP groups, but not in the Preop-MP group. *P <
.0001; †P = .004; ‡P = .002.
Fig 3. The A-a gradient is shown for each group at each
experimental stage. In the control group, the A-a gradient was
significantly higher than before CPB (baseline) and at 30
minutes (Post 30) and 60 minutes (Post 60). In the Prime-MP
group, the A-a gradient was significantly higher than baseline
at Post 60, although in the Preop-MP group, A-a gradient was
not significantly higher than baseline at either stage after
CPB. *P = .0001; †P = .02.
Fig 4. The net extracorporeal circuit fluid balance is shown
for each group. Each group had a positive ending balance.
The pump balance for the Preop-MP group was significantly
lower than that of the control group. The balance for the
Prime-MP group was intermediate between the control and
Preop-MP groups, but the differences did not reach statistical
significance. *P = .001; †P = .07 versus control and .05 ver-
sus Preop-MP.
cantly higher at the end of the study than the preopera-
tive body weights (Table II). This was attributed to an
increase in total body water. The animals in the Preop-
MP group gained significantly less water weight per
kilogram than the control group (96 g/kg vs 160 g/kg;
P = .003) and the Prime-MP group (96 g/kg vs 150
g/kg; P = .01). There was no significant difference
between the control and Prime-MP groups (Table II).
There was also a significant difference between the
groups in lung water content at the end of the study (P
= .0002). The lungs in the Preop-MP group contained
significantly less water than the control group (82.9%
vs 86.4%; P = .001) and the Prime-MP group (82.9%
vs 83.9%; P = .026). There was no significant differ-
ence in lung water content between the Preop-MP and
Prime-MP groups.
Pump balance. Each group had a net positive pump
balance at the end of CPB. There was a significant dif-
ference between the groups in the magnitude of the
positive pump balance (P = .002). The control group
had a significantly more positive balance (per body
weight) than the Preop-MP group (120 mL/kg vs 61
mL/kg; P = .0010). The Prime-MP group fell between
the control and Preop-MP groups (94 mL/kg) and was
significantly different from the Preop-MP group (P =
.053) but not the control group (P = .070). These data
are shown in Fig 4.
Discussion
Few would debate that CPB causes a substantial
inflammatory response. In infants, 2 of the most mor-
bid manifestations of this host response are pulmonary
dysfunction and increased total body water gain. These
can result in longer mechanical ventilation require-
ments and longer intensive care unit stays and in pul-
monary and cardiac dysfunction and may necessitate
delayed chest closure. All of these increase the likeli-
hood of complications and increase hospital costs.
Numerous techniques have been investigated with the
goal of finding one that reduces this inflammatory
response to CPB. A desirable method would be one that
is not only effective, but available, relatively easy to
implement, and not prohibitively expensive and that
works at multiple levels of the inflammatory cascade.
Studies have shown that circulating levels of various
cytokines (interleukin-6 [IL-6], IL-8, IL-10, tumor
necrosis factor-a , C-reactive protein) and products of
complement activation are all elevated in response to
CPB. Because of the strong anti-inflammatory effect of
glucocorticoids, it is logical to assume that the admin-
istration of these agents would blunt this inflammatory
response. Many studies have in fact been done to inves-
tigate the role of steroids in ameliorating the inflam-
matory response to CPB. The earliest of these stud-
ies11-13 used relatively crude or nonspecific measures
such as graft flows, urine output, and chest radiograph
appearance to evaluate the effect of glucocorticoids
administered before or during CPB. Although these
studies suggested a beneficial effect from glucocorti-
coid administration, this received little attention in the
literature until recently.
With the discovery of cytokines as inflammatory
mediators and the ability to measure many of these mol-
ecules, investigators were able to document the ability
of glucocorticoids to blunt the CPB-related increases in
circulating levels of many of these inflammatory medi-
ators, including IL-6, IL-8, TNF-a , CD11b, leukotriene
B4, and tissue plasminogen activator.4,6,14-19 Most of
these studies, however, fail to correlate measures of
physiologic injury with the reduction of cytokine levels.
It is not clear, for example, if reducing the circulating
level of TNF-a by 50% is sufficient to prevent severe
postoperative pulmonary hypertension or an increase in
total body edema and therefore to improve outcome.
Numerous studies suggest that lung injury is a result of
inflammatory mediators. In 2 studies by Brigham,21,22
lung injury in a model of endotoxemia was correlated
with increased levels of various cytokines. These stud-
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Table II. Body weight and lung water content data
Variable Stage Control Prime-MP Preop-MP
Body weight (kg) Baseline 2.5 ± 0.2 2.3 ± 0.3 2.5 ± 0.4
Post 2.9 ± 0.2* 2.7 ± 0.3* 2,5 ± 0.4†
Water weight gain/body weight (g/kg) Post 160 ± 27‡ 150 ± 30§ 96 ± 14
Lung water (%) Post 86.4 ± 1.5II 83.9 ± 0.7¶ 82.9 ± 0.5
*P < .001 vs baseline.
†P = .003 vs baseline.
‡P = .003 vs Preop-MP.
§P = .01 vs Preop-MP.
IIP = .001 vs Preop-MP.
¶P = .026 vs Preop-MP.
ies suggest that the administration of corticosteroids is
more effective in ameliorating this insult than either
cyclooxygenase inhibitors or leukocyte depletion.
These observations led us to design this study that
used methylprednisolone as a potent anti-inflammatory
agent and to measure pulmonary function both as an
indicator of postbypass inflammation and of outcome.
Smith,23 in a study of butylated hydroxytoluene–
induced lung injury in mice, suggested that the timing of
the dose of steroids is important in producing an effect.
In light of this observation we found it surprising that in
most studies steroids were given in close proximity to
CPB. Glucocorticoids exert their anti-inflammatory
effects by a mechanism of action that involves binding
to an intracellular receptor. The steroid-receptor com-
plex is then transported into the nucleus where it affects
mRNA transcription and, consequently, protein transla-
tion. Because alterations in the translation of specific
proteins is required, it is unlikely that the maximum
effect of the administered steroid would be realized
immediately. Despite this, virtually all studies examin-
ing the effect of glucocorticoids on the inflammatory
response to CPB involve administration of the drug only
shortly before the inflammatory stimulus—usually
either on induction of anesthesia, only minutes before
CPB, or into the CPB pump prime itself—and some-
times not until after perfusion had com-
menced.4,11,19,24-27 Because the activation of blood ele-
ments occurs when they contact the artificial surfaces of
the extracorporeal circuit, it is logical to assume that to
have an optimal effect, glucocorticoids should be
administered hours before the initiation of CPB.
Our study is unique in that it uses a neonatal model,
that steroids are given in 2 doses beginning 8 hours
before the operation, and that specific measures of pul-
monary function are taken. The dosing regimen was
somewhat arbitrary but was based on the presumed
need to give at least 1 dose of methylprednisolone suf-
ficiently early that its maximal effects would be
achieved. The adverse effects of CPB in this model
(including the highly reproducible severe pulmonary
hypertension and associated poor lung compliance) and
extracellular fluid accumulation are clinically similar to
what is sometimes observed in infants undergoing
CPB. In virtually every variable measured in this study,
a protective effect was observed in the Preop-MP
group, that is from administering high-dose methyl-
prednisolone beginning 8 hours before the operation. In
addition, in the case of each parameter measured, the
outcome for the Prime-MP group was intermediate
between the control and Preop-MP groups, indicating
that administering methylprednisolone in the pump
prime only (correlating with the onset of the inflamma-
tory stimulus) conferred a beneficial effect, but that the
maximum benefit of the glucocorticoid treatment is not
achieved with this dosing strategy. The mechanism
responsible for the partial salutary effect observed in
the Prime-MP group is not clear but may involve the
immediate release of immunomodulating substances
after receptor binding.
One limitation of the current study is that inflamma-
tory mediators were not measured to correlate with the
physiologic indicators of the inflammatory response to
CPB. Although this is somewhat more difficult in the
pig than in human beings or mice because of the avail-
ability of reagents, work is in progress to document the
levels of IL-6 and TNF-a . In addition, some may argue
that the risks of high-dose glucocorticoid administra-
tion may outweigh the benefits. Mayumi and col-
leagues28 suggest that the combination of CPB and
high-dose methylprednisolone is immunosuppresive
based on blood cell count and cytokine production.
There are also concerns about gastric ulceration. How-
ever, there are no data to suggest that patients receiving
steroids and undergoing CPB have higher infectious
complications, and it is generally believed that admin-
istration of a single high dose of glucocorticoids does
not carry the risks of wound-healing complications and
ulcerogenesis as long-term use does. An additional lim-
itation of our study is that it was not randomized or
blinded to the dosing regimen. The reason for this was
that the experiment was first conducted with just the
control and Preop-MP groups. It was clear even before
the data were analyzed that the experimental group tol-
erated CPB better than the control group, so a second
experimental group was added to determine whether
differences existed between the novel and more con-
ventional dosing strategies. The findings must be con-
sidered with this fact in mind.
In summary, the administration of high-dose methyl-
prednisolone 8 hours and immediately before opera-
tions involving CPB in infants offers a relatively inex-
pensive and readily available means of protection from
the inflammatory response to CPB compared with no
treatment. Furthermore, the use of this dosing strategy
is superior to one in which methylprednisolone is
administered at or around the time of the inflammatory
stimulus of CPB. The use of this strategy may substan-
tially reduce morbidity after CPB and hospital costs,
especially if used in selected high-risk patients.
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Discussion
Dr Carl L. Backer (Chicago, Ill). Our experience at
Children’s Memorial Hospital used a slightly intermediate
technique where we administered intravenous dexametha-
sone (Decadron) 1 to 2 hours before CPB. We found that this
resulted in findings similar to yours. There was a decrease in
inflammatory mediator release of both IL-6 and tumor necro-
sis factor and also an improved clinical course as evidenced
by less postoperative fever, less fluid administration, and
fewer days of ventilation. 
If you had to pick either the single dose in the prime or an
oral dose preoperatively, which would you choose? I noted
that in several of the results, the dose in the prime did signif-
icantly improve the outcome. 
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What do you think about administering the dexamethasone
1 to 2 hours before CPB, which is relatively easy to facilitate?
Dr Lodge. If I had to choose between preoperative oral
dose and an intravenous dose, which was given only 1 or 2
hours before bypass, I would probably choose the oral dose
given 8 hours before bypass, simply based on the results that
we have seen here and the known mechanism of action of
steroids, which then take probably 48 hours to reach peak
effect. 
The answer to your second question is relatively similar,
but there is no question that our results showed some benefit
to giving steroids in the pump prime. I would expect that sim-
ilar results would be observed if an intravenous dose was
administered, say, at the induction of anesthesia. On the basis
of those data, there is some benefit to doing that. However, if
it is feasible, a dose that was begun significantly before the
induction of anesthesia (the timing that we used was 8 hours)
would be more beneficial.
Dr John H. Calhoon (San Antonio, Tex). We have been
using steroids while the patient is undergoing bypass for years
for children’s hearts and intraoperatively during our transplan-
tations. In San Antonio (after a fortuitous visit to Duke about
8 months ago), we started using the steroids the night before
as they had been doing clinically. We, too, like Dr Backer’s
group in Chicago, saw a dramatic decrease in postoperative
weight gain and ventilator and fluid requirements. 
I think this article is going to be an important one. It should
make us all think carefully about our approach to CPB con-
duct and probably transplantation with its attendant ischemia-
reperfusion response. 
Why is there an intermediate response with steroids given
at the time of pump institution? Could you share with us any
of the clinical results that you all have started having? 
Dr Lodge. The effect observed in the intermediate group
was inconsistent, but I think the data show that there was
some benefit to administering steroids in the prime. There
may be two reasons for that. First, more recent work on the
mechanism of action of steroids has shown that there may be
some membrane receptors that may mediate some of the ear-
lier effects. In addition, steroids are thought to have a mem-
brane-stabilizing effect and most important, in this case per-
haps, stabilizing lysosomes that can release toxic products. 
As far as the clinical data go, Dr Jaggers has actually been
collecting some of these data and using this strategy in some
of the patients that have undergone operation recently at
Duke. His results preliminarily show significant decreases in
ventilator time and the need for delayed chest closure, which
translated into decreased intensive care unit length of stays
and decreased overall costs.
Dr Bradley Allen (Chicago, Ill). These findings are similar
to those of our recent study, which demonstrated that the
inflammatory response in neonates could be decreased by
removing white cells from the CPB circuit. If I understood
your presentation correctly, the group that received preopera-
tive steroids (Preop-MP) actually received 2 doses of methyl-
prednisolone, whereas the other steroid group (Prime-MP)
received only 1 dose. Therefore how do you know that it is the
timing of the steroid infusion and not the fact that you gave
twice as much methylprednisolone to the Preop-MP group?
Dr Lodge. We do not know that. That is a good question. I
think it is worth looking into some of that information, specif-
ically a dose-response curve and the possibility of giving a
dose that starts 8 hours before the operation in addition to
a dose that is given right before the operation, compared with
a group that receives 1 dose right before the operation. We do
not have those data and did not include that group in our study.
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